Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to <i>Onchocerca volvulus</i> in Mice and Non-Human Primates
Onchocerciasis remains a debilitating neglected tropical disease. Due to the many challenges of current control methods, an effective vaccine against the causative agent <i>Onchocerca volvulus</i> is urgently needed. Mice and cynomolgus macaque non-human primates (NHPs) were immunized wi...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/7/1212 |
| _version_ | 1797587293658152960 |
|---|---|
| author | Nathan M. Ryan Jessica A. Hess Erica J. Robertson Nancy Tricoche Cheri Turner Jenn Davis Nikolai Petrovsky Melissa Ferguson William J. Rinaldi Valerie M. Wong Ayako Shimada Bin Zhan Maria Elena Bottazzi Benjamin L. Makepeace Sean A. Gray Darrick Carter Sara Lustigman David Abraham |
| author_facet | Nathan M. Ryan Jessica A. Hess Erica J. Robertson Nancy Tricoche Cheri Turner Jenn Davis Nikolai Petrovsky Melissa Ferguson William J. Rinaldi Valerie M. Wong Ayako Shimada Bin Zhan Maria Elena Bottazzi Benjamin L. Makepeace Sean A. Gray Darrick Carter Sara Lustigman David Abraham |
| author_sort | Nathan M. Ryan |
| collection | DOAJ |
| description | Onchocerciasis remains a debilitating neglected tropical disease. Due to the many challenges of current control methods, an effective vaccine against the causative agent <i>Onchocerca volvulus</i> is urgently needed. Mice and cynomolgus macaque non-human primates (NHPs) were immunized with a vaccine consisting of a fusion of two <i>O. volvulus</i> protein antigens, <i>Ov</i>-103 and <i>Ov</i>-RAL-2 (<i>Ov</i>-FUS-1), and three different adjuvants: Advax-CpG, alum, and AlT4. All vaccine formulations induced high antigen-specific IgG titers in both mice and NHPs. Challenging mice with <i>O. volvulus</i> L3 contained within subcutaneous diffusion chambers demonstrated that <i>Ov</i>-FUS-1/Advax-CpG-immunized animals developed protective immunity, durable for at least 11 weeks. Passive transfer of sera, collected at several time points, from both mice and NHPs immunized with <i>Ov</i>-FUS-1/Advax-CpG transferred protection to naïve mice. These results demonstrate that <i>Ov</i>-FUS-1 with the adjuvant Advax-CpG induces durable protective immunity against <i>O. volvulus</i> in mice and NHPs that is mediated by vaccine-induced humoral factors. |
| first_indexed | 2024-03-11T00:35:06Z |
| format | Article |
| id | doaj.art-46f23ced16cf402685e56905723070a0 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T00:35:06Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-46f23ced16cf402685e56905723070a02023-11-18T21:41:12ZengMDPI AGVaccines2076-393X2023-07-01117121210.3390/vaccines11071212Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to <i>Onchocerca volvulus</i> in Mice and Non-Human PrimatesNathan M. Ryan0Jessica A. Hess1Erica J. Robertson2Nancy Tricoche3Cheri Turner4Jenn Davis5Nikolai Petrovsky6Melissa Ferguson7William J. Rinaldi8Valerie M. Wong9Ayako Shimada10Bin Zhan11Maria Elena Bottazzi12Benjamin L. Makepeace13Sean A. Gray14Darrick Carter15Sara Lustigman16David Abraham17Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USADepartment of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USADepartment of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USALaboratory of Molecular Parasitology, Lindsey F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USAPAI Life Sciences Inc., Seattle, WA 98102, USAPAI Life Sciences Inc., Seattle, WA 98102, USAVaxine Pty Ltd., Bedford Park, Adelaide, SA 5042, AustraliaAlpha Genesis Inc., Yemassee, SC 29945, USAAlpha Genesis Inc., Yemassee, SC 29945, USAIDEXX BioAnalytics, West Sacramento, CA 95605, USADivision of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USATexas Children’s Hospital Center for Vaccine Development, Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USATexas Children’s Hospital Center for Vaccine Development, Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USAInstitute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool L3 5RF, UKPAI Life Sciences Inc., Seattle, WA 98102, USAPAI Life Sciences Inc., Seattle, WA 98102, USALaboratory of Molecular Parasitology, Lindsey F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USADepartment of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USAOnchocerciasis remains a debilitating neglected tropical disease. Due to the many challenges of current control methods, an effective vaccine against the causative agent <i>Onchocerca volvulus</i> is urgently needed. Mice and cynomolgus macaque non-human primates (NHPs) were immunized with a vaccine consisting of a fusion of two <i>O. volvulus</i> protein antigens, <i>Ov</i>-103 and <i>Ov</i>-RAL-2 (<i>Ov</i>-FUS-1), and three different adjuvants: Advax-CpG, alum, and AlT4. All vaccine formulations induced high antigen-specific IgG titers in both mice and NHPs. Challenging mice with <i>O. volvulus</i> L3 contained within subcutaneous diffusion chambers demonstrated that <i>Ov</i>-FUS-1/Advax-CpG-immunized animals developed protective immunity, durable for at least 11 weeks. Passive transfer of sera, collected at several time points, from both mice and NHPs immunized with <i>Ov</i>-FUS-1/Advax-CpG transferred protection to naïve mice. These results demonstrate that <i>Ov</i>-FUS-1 with the adjuvant Advax-CpG induces durable protective immunity against <i>O. volvulus</i> in mice and NHPs that is mediated by vaccine-induced humoral factors.https://www.mdpi.com/2076-393X/11/7/1212<i>Onchocerca volvulus</i>vaccinedurabilityadjuvantmicenon-human primates |
| spellingShingle | Nathan M. Ryan Jessica A. Hess Erica J. Robertson Nancy Tricoche Cheri Turner Jenn Davis Nikolai Petrovsky Melissa Ferguson William J. Rinaldi Valerie M. Wong Ayako Shimada Bin Zhan Maria Elena Bottazzi Benjamin L. Makepeace Sean A. Gray Darrick Carter Sara Lustigman David Abraham Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to <i>Onchocerca volvulus</i> in Mice and Non-Human Primates Vaccines <i>Onchocerca volvulus</i> vaccine durability adjuvant mice non-human primates |
| title | Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to <i>Onchocerca volvulus</i> in Mice and Non-Human Primates |
| title_full | Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to <i>Onchocerca volvulus</i> in Mice and Non-Human Primates |
| title_fullStr | Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to <i>Onchocerca volvulus</i> in Mice and Non-Human Primates |
| title_full_unstemmed | Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to <i>Onchocerca volvulus</i> in Mice and Non-Human Primates |
| title_short | Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to <i>Onchocerca volvulus</i> in Mice and Non-Human Primates |
| title_sort | adjuvanted fusion protein vaccine induces durable immunity to i onchocerca volvulus i in mice and non human primates |
| topic | <i>Onchocerca volvulus</i> vaccine durability adjuvant mice non-human primates |
| url | https://www.mdpi.com/2076-393X/11/7/1212 |
| work_keys_str_mv | AT nathanmryan adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT jessicaahess adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT ericajrobertson adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT nancytricoche adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT cheriturner adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT jenndavis adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT nikolaipetrovsky adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT melissaferguson adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT williamjrinaldi adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT valeriemwong adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT ayakoshimada adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT binzhan adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT mariaelenabottazzi adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT benjaminlmakepeace adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT seanagray adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT darrickcarter adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT saralustigman adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates AT davidabraham adjuvantedfusionproteinvaccineinducesdurableimmunitytoionchocercavolvulusiinmiceandnonhumanprimates |